Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
García Sanz, R
7578  Ergebnisse:
Personensuche X
?
1

Consensus guidelines for the optimal management of adverse ..:

Palumbo, A. ; Davies, F. ; Kropff, M....
Annals of Hematology.  89 (2010)  8 - p. 803-811 , 2010
Link: https://doi.org/10.1007/..
 
?
2

CELL‐FREE DNA KINETICS DECIPHER POTENTIAL MECHANISMS OF ACT..:

Khouja, M. ; Genuardi, E. ; Ferrero, S....
Hematological Oncology.  41 (2023)  S2 - p. 181-183 , 2023
Link: https://doi.org/10.1002/..
 
?
3

FIVE‐YEAR UPDATE OF THE FIRST‐LINE IMCL‐2015 GELTAMO STUDY...:

Giné, E. ; Medina‐Herrera, A. ; Cruz, F. de la...
Hematological Oncology.  41 (2023)  S2 - p. 148-150 , 2023
Link: https://doi.org/10.1002/..
 
?
4

Baseline‐PET derived metrics are the most relevant factors ..:

Zaucha, J. M. ; Picardi, M. ; Kurlapski, M....
Hematological Oncology.  41 (2023)  S2 - p. 350-351 , 2023
Link: https://doi.org/10.1002/..
 
?
5

MIPI53. A NEW PROGNOSTIC INDEX FOR MANTLE CELL LYMPHOMA:

Boente, M. Bastos ; Sánchez, M. Alcoceba ; Bailón, A. Navarro...
Hematological Oncology.  41 (2023)  S2 - p. 748-748 , 2023
Link: https://doi.org/10.1002/..
 
?
6

Phase 1 trial of EO2463 peptide‐based immunotherapy as mono..:

Pinto, A. A. ; Bosch, F. ; Bisneto, J. C. Villasboas...
Hematological Oncology.  41 (2023)  S2 - p. 581-582 , 2023
Link: https://doi.org/10.1002/..
 
?
7

P1161: ASPEN: LONG-TERM FOLLOW-UP RESULTS OF A PHASE 3 RAND..:

Dimopoulos, M. ; Opat, S. ; D'Sa, S....
HemaSphere.  6 (2022)  - p. 1048-1049 , 2022
Link: https://doi.org/10.1097/..
 
?
8

P1115: A MULTICENTER PHASE 1/2 TRIAL OF EO2463, A MICROBIAL..:

Zinzani, P. L. ; Ansell, S. M. ; Bosch, F....
HemaSphere.  6 (2022)  - p. 1005-1006 , 2022
Link: https://doi.org/10.1097/..
 
?
9

A strategic reflection for the management and implementatio..:

Zozaya, N. ; Villaseca, J. ; Abdalla, F....
Clinical and Translational Oncology.  24 (2022)  6 - p. 968-980 , 2022
Link: https://doi.org/10.1007/..
 
?
10

P1256: A NOVEL DROP-OFF DIGITAL PCR ASSAY FOR CXCR4 MUTATIO..:

Drandi, D. ; Ferrante, M. ; Zibellini, S....
HemaSphere.  6 (2022)  - p. 1141-1142 , 2022
Link: https://doi.org/10.1097/..
 
?
11

P1128: CLINICAL FEATURES AND OUTCOME OF PATIENTS WITH CASTL..:

Navarro, J. T. ; Celades, C. ; García, O....
HemaSphere.  6 (2022)  - p. 1018-1019 , 2022
Link: https://doi.org/10.1097/..
 
?
12

P1083: BRENTUXIMAB VEDOTIN, ETOPOSIDE, SOLUMEDROL, HIGH DOS..:

Garcia-Sanz, R. ; Martínez, C. ; De la Cruz, F....
HemaSphere.  6 (2022)  - p. 973-974 , 2022
Link: https://doi.org/10.1097/..
 
?
13

Booster effect after SARS-CoV-2 vaccination in immunocompro..:

Piñana, José Luis ; García Sanz, R ; Martino, Rodrigo...
Blood Advances, 2022, vol. 6, num. 3, p. 848-853.  , 2022
Link: https://hdl.handle.net/1..
 
?
14

Impact of the COVID-19 pandemic on the care of cancer patie..:

Amador, M. ; Matias-Guiu, X. ; Sancho-Pardo, G....
ESMO Open.  6 (2021)  3 - p. 100157 , 2021
Link: https://doi.org/10.1016/..
 
?
15

A phase 2 study of ibrutinib in combination with bortezomib..:

Hájek, R ; Pour, L ; Ozcan, M...
European Journal of Haematology.  , 2020
Link: https://ddd.uab.cat/reco..
 
1-15